Board & Management

Anders Essen-Möller, Chairman. Born in 1941. M.Sc. Founder and former CEO of Diamyd Medical. Board member since 1996, Chairman since 2007. Anders Essen-Möller also founded Synectics Medical AB, which was sold to Medtronic Inc. in 1996. Other assignments: Member of the Armea AB board. Holdings in Diamyd as of August 31, 2009: 561,671 A shares; 231,902 B shares; and 10,000 employee options 2007/2010.

Lars Jonsson, Independent Board Member. Born in 1948. B.Sc., Stanford Graduate Business School Senior Executive Program. Lars Jonsson has been a Board member since 2007. Chairman and CEO of Stellar Holdings. Swedish Honorary Consul in Seattle, founder and majority owner of the international group Stellar Holdings. Ambassador for Barndiabetesfonden (The Childhood Diabetes Foundation). Other assignments: None. Holdings in Diamyd as of August 31, 2009: 600 B shares.

Sam Lindgren, Independent Board member. Born in 1955. MD, Ph.D., MBA. Sam Lindgren has been a Board member since 2007. More than 15 years' experience from leading positions in the pharmaceutical industry, in the areas of diabetes (Novo Nordisk), CNS (Lundbeck) and asthma (Astra). Currently Senior Director of Gambro Lundia AB. Other assignments: None. Holdings in Diamyd as of August 31, 2009: 500 B shares.

Henrik Bonde, Independent Board Member. Born in 1972. M.Sc. in Business Administration. Board member since 2008. Henrik Bonde represents the Östersjöstiftelsen. He is the Chief Investment Officer of the Östersjöstiftelsen and the Gålöstiftelsen. Other assignments: Member of the Boards of Morphic Technologies AB, Iris Holding AB and Spectracure AB. Holdings in Diamyd as of August 31, 2009: 400 B shares.

Maria-Teresa Essen-Möller, Board Member. Born in 1970. M.Sc. in Business Administration. Board member since 2009. Founder and CEO of Essen-Möller Consulting. Maria-Teresa Essen-Möller was Head of Investor Relations and Corporate Communications for Diamyd 1997-1999. Other Assignments: Board member of Stiftelsen Adolf Fredriks och Gustav Vasa Barnkrubba. Holdings in Diamyd as of December 31, 2009: 18 000 B Shares.

Göran Pettersson, Independent Board Member. Born in 1945. M.Pharm.Sc., MBA. Board member since 2009. 40 years experience from leading positions in Sweden and abroad in Astra, KabiVitrum, Pharmacia, Pharmacia&UpJohn and Meda. Other assignments: Chairman in Medivir AB, OxyPharma AB and Vivoxid Oy. Member of the boards of Recipharm AB,and Pfizer Pensionsstiftelse 1. Holdings in Diamyd as of January 31, 2010: 0.

Elisabeth Lindner, President and CEO. Born in 1956. M.Sc. and MBA, Stockholm and Uppsala. Long-standing experience with Pharmacia Corporation and Octapharma AG. Elisabeth Lindner has been Diamyd's President and CEO since 2008. Other assignments: Member of the Board of BioInvent International AB (publ) and SwedenBio, CEO and Board member of Biosource Europe AB, Member of the Board of the Royal Swedish Academy of Engineering Sciences (IVA) and European Framework 7, Advisory Group for Health Research. Holdings in Diamyd as of August 31, 2009: 9,100 B shares; 10,000 employee options 2007/2010; and 42,900 employee options 2008/2011.

Darren Wolfe, CEO, Diamyd Inc., USA. Born in 1968. Ph.D. in Molecular Biology and Biochemistry, Pennsylvania State University. Darren Wolfe was previously a Research Assistant Professor in the Department of Molecular Genetics and Biochemistry at the University of Pittsburgh. Darren Wolfe has worked for Diamyd since 2006. Other assignments: None. Holdings in Diamyd as of August 31, 2009: 2,500 B shares; 10,000 employee options 2007/2010; and 16,500 employee options 2008/2011.

Erika Hillborg, Director of Clinical Development. Born in 1967. M.Sc. in Biomedicine from the Karolinska Institute in Stockholm, with a Science Journalism degree from Uppsala University. Erika Hillborg has worked for Diamyd since 2006. Other assignments: None. Holdings in Diamyd as of August 31, 2009: 8,850 B shares; 10,000 employee options 2007/2010; and 16,500 employee options 2008/2011.

Peter Zerhouni, Director of Business Development. Born in 1972. M.Sc. in Biology and a B.Sc. in Economics & Business Administration from Lund University and UC Berkeley. From 1999 to 2006 Peter Zerhouni held various positions at ING Bank in Brussels and Amsterdam, most recently within Structured Finance. Peter Zerhouni joined Diamyd in 2006. Other assignments: None. Holdings in Diamyd as of August 31, 2009: 500 B shares; 10,000 employee options 2007/2010; and 16,500 employee options 2008/2011.

Anna Styrud, Chief Financial Officer. Born in 1961. BSc in Business Administration from Uppsala University. Previous experience includes Group Treasurer of Vasakronan and various positions within finance, treasury and control at Fläkt AB and National Board of Public Building. Anna Styrud joined Diamyd in 2010. Other assignments: None. Holdings in Diamyd Medical AB as of May 31, 2010: 500 B-shares and 25,000 employee options 2009/2012.